Introduction
Both Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) with intermittent, episodic progression. CD is an inflammatory disease of the gastrointestinal mucosa, 1 which is classified and defined by the gastrointestinal region involved and may be localized or extensive. 2, 3 UC is characterized by periods of active disease and remission that result in inflammation of the colonic mucosa. It is normally confined to the colon, with occasional ileal involvement, and it always involves the rectum. It may be classified as ulcerative proctitis (inflammation of the anus and rectum), left colitis (inflammation of the sigmoid and descending colon), or extensive colitis (from the rectum to the transverse colon and beyond) ( Figure 1) . 4, 5 It is a severe disease that can be potentially life-threatening.
IBD symptoms contribute to poorer quality of life (QoL) during active disease episodes, 4 and severe attacks are also characterized by malaise, fever, and anorexia. 5 Initial symptoms and signs of CD can be more subtle than those of UC, but most commonly include chronic diarrhea, abdominal pain, and weight loss. Blood and/or mucus may be seen in the stool, but bloody diarrhea is less common in patients with CD than in those with UC, and patients with CD are more likely to have abdominal pain or nonspecific abdominal symptoms. 1, 3 The etiology of both CD and UC is unknown, although both diseases are thought to be caused by a combination of genetic and environmental factors. 5, 7 Although IBD onset can occur at any age, the peak age of onset is approximately 15-30 years in both CD and UC. 4, 8 Incidence and prevalence of IBD have increased in the past 50 years, and appear to be higher in developed countries -particularly in Europe and the US. In Europe, an estimated 1 million patients have CD, and 1.4 million have UC. 7 Reported CD and UC incidence and prevalence vary considerably, particularly among different populations. 7, 9, 10 Increasing trends in both UC and CD incidence have been reported almost globally, 11, 12 and particularly high rates of IBD have been reported in certain regions, one of which is The Netherlands. 13 IBD incidence rates for The Netherlands of 6.9 per 100,000 for CD and 10 per 100,000 for UC have been reported. 13 
Treatment
The main goal of treatment for both UC and CD is to rapidly induce and maintain disease remission; as the precise disease etiology is unknown, therapy cannot be directly targeted to the cause of the disease. Symptoms are managed with medication, lifestyle, and dietary change, and treatment can be either maintenance for remission or acute to treat inflammation and any associated infection. 3, 5 Disease site is important in IBD therapy; some drugs with local activity (such as mesalazine aminosalicylate preparations and budesonide) may be more effective when delivered topically. 2 Both aminosalicylate and corticosteroid therapy can be administered orally, intravenously, or rectally. Enema administration involves the delivery of fluid via the anus into the rectum and lower intestine using a flexible tube with a hole in the tip, which can be attached to a delivery container or solution bag ( Figure 2 ). There are two main enema types: (1) evacuation enemas, which facilitate the passage of feces, and (2) retention enemas, which are designed to be retained in the rectum for a longer period of time and are used for drug delivery. 14, 15 Aminosalicylate enemas are effective in improving symptoms and inducing and maintaining remission in patients with IBD. 2, 16 Rectal formulations can optimize drug delivery to the affected region, while minimizing systemic absorption of the drug and reducing associated side effects, 4,17 but require drug retention, which can be difficult for patients. 4, 18 Rectally administered treatments can be more effective than orally delivered treatments, 19, 20 and have shown efficacy in patients unresponsive to oral therapy. 18, 21 Combination oral and rectal therapy is also effective in inducing and maintaining remission in patients with UC, and can be more effective than oral therapy alone. 20, 22 The European Crohn's and Colitis Organization consensus guidelines on treatment of CD recommend that therapy for active, mild-to-medium severity left-sided UC should begin with combination therapy of aminosalicylate enema plus oral mesalazine; 2, 16 this is also supported by the British Society of Gastroenterology 6 and American practice guidelines. 20, 21 It is also important to tailor therapy to the individual patient, and to involve the patient in all therapeutic decisions.
2,16
Therapy adherence and QoL in patients with IBD Most patients with IBD will need lifelong therapy, and adherence is a key factor in treatment success. Improving patient adherence is an important means of improving QoL and long-term health outcomes in patients with UC. 4 Methods of encouraging self-management, such as a prototype Internet diary for patients with CD, provide opportunities for improved QoL. 23 QoL is very important in patients with IBD, 24 as many patients live with a considerable symptom burden, despite medical treatment, 3, 5 and QoL is frequently impaired. 25, 26 Although disease activity has a major effect on QoL, 27 fatigue, sleep disturbance, and general impact on normal life are also important consequences of IBD. 24 Quality of care (particularly in relation to provision of information), cost, and courtesy have also been shown to affect QoL in patients with IBD. 28 
Enema adherence
Adherence with topical therapies can be poor, 22 and they are more likely to be associated with nonadherence than oral therapy. 29, 30 Enemas can be uncomfortable for the patient; administration can stimulate the urge to defecate, and this, combined with the need for enema retention, can cause patient embarrassment and discomfort. Complications may include leakage, bloating, irritation, bleeding, swelling, or prolapse of the rectal tissue. 15, 18 As lower adherence may be related to lower remission rates in patients with IBD, 31 it is important to maximize patient comfort and tolerance with enema delivery.
There is little discussion in the literature of patient views on enema use and satisfaction. Many studies of enema tolerability focus on comparisons between enema types, rather than patient views and feedback on the enema itself. 17, 32 Further, many studies consider therapy for either CD or UC, without combining considerations from patients with IBD in general. Patient feedback on enema use is extremely valuable. It is important to have a greater understanding of factors inhibiting adherence with topical treatment, and how this can be used to improve patient comfort.
Use of enemas is not always popular with patients, 33, 34 however, and adherence can be poor. [29] [30] [31] Current literature has little information regarding patient views on enema use, and the relationships between this and treatment adherence. The objective of this study was to gain insight from people with CD or UC in The Netherlands (an area with high incidence of IBD) on their experiences with enema use, and their feelings and viewpoints on enema use. The research question was: what views do patients with IBD have on enema use and delivery system/mode?
Methods

Data collection
An online questionnaire-based study of adult patients with CD, UC, or other (unspecified) intestinal problems, who had personal experience with enema use and were willing to discuss their experiences and views, was performed. The questionnaire was developed by Patient Intelligence Panel (PIP Health, London, UK; a patient research company) in collaboration with the authors, and sent by email to members of PIP Health's online Patient Intelligence Panel (www.piphealth.nl) during the period December 1-10, 2012. All participants were aged 18 years or over, had been physician diagnosed with either CD, UC, or other intestinal problems, and had previously indicated a willingness to participate in surveys on their IBD. The 254 Dutch panel members were sent an email containing a link to an online survey. In total, 112 panel members completed the survey -a response rate of 44%. Data analysis took place in December 2012. The questionnaire consisted of 24 questions focusing on: respondents' sociodemographic and clinical characteristics, use of enema (drug type and mode of administration), patient adherence, perceived advantages/disadvantages of enema use and patient views on ideal enema design, and patient perceptions about their medication for IBD and views on drugs and medical care in general. Patient responses to these last two questions were assessed using the validated Beliefs about Medicine Questionnaire (BMQ). 35 Patient adherence to medication was measured through the Medication Adherence Report Scale (MARS) scale using a ranking scale of one to five. 36, 37 The questionnaire was also designed to obtain respondent opinions and feedback on enema use and ideal design, assessed with open questions. Particular focus was given to the analysis of respondent answers to the following questions and scales to determine patient views and satisfaction with their treatment:
• Satisfaction with enema use (on a ranking scale of one to seven), and reasons for dissatisfaction (if any).
• Adherence to medication administered by enema using the MARS-5 scale (on a ranking scale of one to five).
• Personal feelings on enema medication using the BMQ (on a ranking scale of one to five).
• Views on suggested improvements in enema design (open, tick-box, and ranking).
Patients' responses to the question: "Are you satisfied with the last enema you used" were rated on a scale of one (very dissatisfied) to seven (very satisfied).
Patients were asked "Do you think you are adherent with your enema medication?," and given a choice of four answers (yes, totally agree; yes, agree; no, disagree; no, completely disagree). The responses to "totally agree" and "agree" were combined to give an overall self-reported adherence rating.
Patient's views on suggested improvements in enema design consisted of three sections. The first was an open question on suggested improvements by respondents when given a picture of a standard enema applicator; respondents were then asked to describe exactly what they liked/ disliked about enema design, and to provide suggestions for improvements. These were then analyzed to identify particular issues/ components/aspects in design suggestion. The second section incorporated a series of four structured questions on enema design, to which respondents could agree/disagree on a ranking scale of one to five using tickboxes; an average ranking score was taken for each question, and the percentage of respondents agreeing with each question was calculated. The third section included a list of eleven potential improvements to enema design, from which respondents were asked to select the three which they felt would be the most important; the percentage of responses to each question was calculated, and selections were ranked in order of popularity.
Respondent feelings on enema medication and on drugs in general were taken using the BMQ. Patient responses to the various questions were combined, and the average scores (by ranking scale) determined to gain an indication of overall trends in patient views.
Results
All 112 respondents lived in The Netherlands and had been diagnosed with UC, CD, or other intestinal problems. All were aged 18 years or over; 29% (n = 32) were male and 71% (n = 80) were female. The largest proportion of patients was aged 36-45 years.
Of the study respondents, 38.5% had a diagnosis of CD (n = 43), 59% were diagnosed with UC (n = 66), and 2.5% reported other intestinal problems (n = 3). One may, therefore, expect patients with UC to have more experience with enema use. Of those respondents with CD, 35% were male (n = 15) and 65% were female (n = 28); of those with UC, 21% were male (n = 14) and 79% were female (n = 52); all three respondents with other intestinal problems were male. Respondents reported use of the following enema medications: mesalazine (Salofalk ® , Pentasa ® , Asacol ® ), corticosteroid (beclomethasone, prednisone, budesonide), and combination (mesalazine/corticosteroid).
Enema use
All respondents who participated in this study had experience with the use of enemas to administer medication as this was a screening question in the survey. A total of 22% (n = 25) of respondents reported that they currently used an enema; the remaining 78% (n = 87) had experience with enema use. Enema medication types used are detailed in Table 1 (if respondents had experience with multiple types of enema medication, the type that they last used was included). The most commonly used enema was Salofalk (35%) and the next most commonly used was Pentasa (15%). Only mesalazine and beclomethasone enemas were included in the study analysis as these are recommended as first-line therapy by European (European Crohn's and Colitis Organization) and Dutch treatment guidelines (Dutch Institute for Healthcare Improvement; CBO) for IBD; other medications used by respondents are detailed in Table 2 .
satisfaction with last enema use
Respondents were asked "Are you satisfied with the last enema you used?," and responses were rated on a scale of one (very dissatisfied) to seven (very satisfied). Scores below four can be interpreted as dissatisfied, and scores above four as satisfied.
As can be seen in Figure 3 , the largest proportion of patients rated themselves as neither greatly satisfied, nor dissatisfied with enema use. At either end of the scale, 12% were totally not satisfied and 7% very satisfied; the average respondent score was 4.3.
Respondents who were not satisfied with their last used enemas were asked to indicate their reasons for dissatisfaction from a selection of answers (Figure 4 ), or to give their own reasons (Table 3) .
As seen in Table 3 , the main two reasons for dissatisfaction were difficulty and awkwardness of administration in both men and women, followed by painful administration due to abdominal cramps and finding it difficult to empty the enema by squeezing (both higher in women). A much greater proportion of men also reported painful administration due to enema circumference (29%) than did women (10%), Notes: *Not included in the study (see Table 2 ); three respondents indicated that they were diagnosed with "intestine problems" and not Crohn's disease or ulcerative colitis. while a much greater proportion of women reported dissatisfaction due to embarrassment (35%) than did men (12%). This information is only from respondents who expressed dissatisfaction with their enema use (n = 57; 17 males and 40 females).
Inconvenience of enema use
Patient perception of enema use in terms of convenience/ difficulty was rated on a scale of one to seven; where one was "very annoying" and seven was "not at all annoying/ difficult" ( Figure 5 ). In general, scores below four can be interpreted as very inconvenient, and scores above four can be seen as satisfactory. Respondents gave an average rating of 3.3. A total score of less than four can be interpreted as a high level of patient annoyance/perception of difficulty with enema use. A total of 21% of respondents rated enema use as "very problematic" (the lowest rating) and only 5% rated enema use as not difficult.
Patient adherence to enema use
When asked "Do you think you are adherent to your enema medication?," 81% of respondents considered themselves adherent (33% responded "absolutely agree" and 54% responded "agree"). The question that followed asked respondents to rate to what extent they considered themselves to be adherent to their enema medication on a scale of one to seven, where one was fully nonadherent and seven was fully adherent; average respondent score was 5.6 -indicating moderate to good compliance. The main reason why respondents demonstrated low scores for adherence (three or less "or" less than four) was that they felt that they do not always need to use the medication. Respondents scoring themselves as low for adherence were further asked why they saw themselves as nonadherent. Notes: *Other reasons given for dissatisfaction with last used enema in the openended field were: causes smelly stools or flatulence; no effect/does not workcomplaint continued; difficulty in retaining medication (leakage); insertion of too much air with medication; irritation of the intestinal wall; and disease activity subsided. some respondents expressed more than one reason for dissatisfaction.
Some felt that the enema was not effective, and therefore they did not think that it was worth using anymore. A small group of others indicated that they did not know exactly why they were nonadherent because they no longer use an enema. All open answers to this question can be found in Table S1 .
Respondents were also requested to report their adherence to enema medication by completing the MARS (Table 4) , in which a score of one indicated "always" and a score of five, "never." Overall, those respondents who used an enema scored highly on the MARS scale, indicating good adherence -particularly with regards to enema dosage and frequency of administration. Slightly lower adherence was seen in regular administration (Table 4) .
switching enema brand
Respondents were asked "Have you ever asked your physician for a different type of enema and changed your enema brand?" Of the 112 respondents, 68% (n = 76) reported never having switched their brand of enema; respondents with CD switched less frequently (74%) than respondents with UC (65%). The 32% of respondents (n = 36) who reported having switched brand were asked "Why did you change to another brand of enema?" and given a choice of responses ( Table 5 ). The most commonly given reason for switching was that the enema was not effective enough (64%), followed by inconvenience of enema use due to pain associated with enema administration (25%).
Enema design and functionality
A picture of an enema applicator ( Figure 6) Notes: One = always; two = common; three = uncommon; four = almost never; five = never. Abbreviation: MARs, Medication Adherence Report scale.
Table 5 Reasons for changing enema brand
Response selected (n = 36) Total n %
The previous enema was not effective enough 23 64% The previous enema was not easy to use due to pain 9 25% The previous enema was difficult to empty 6 17% With the previous enema I could not contain the medications inside of me
19%
The previous enema was not easy to use due to difficulties inserting the enema 6 17%
Other reason given 5 14%
no opinion or just found no issues with the enema design and functionality). The remaining 71 respondents gave a variety of suggestions for improvements (Table S2 ). Overall, two major points were made. Firstly, that the bottle is often clumsy to handle and hard to empty completely by squeezing. Secondly, that the tip of the enema was hard and could be painful to insert; the tip could be softened to make it less painful during insertion. The point was also made that introducing a curved or angled delivery tube may improve retention of medication, and may also reduce introduction of air with the enema, which can lead to trapped wind. The answers of all 112 respondents to this open question are available online at www.piphealth.nl.
Closed questions/statements drafted by the project coordinator at PIP Health were then asked, with the respondents encouraged to agree or disagree on a scale of one to five -with one being "strongly agree" and five being "totally disagree." All scores below three may therefore be interpreted as a positive opinion regarding the statement. Questions and patient responses are given in Table 6 . The highest score was given to the statement: "It would be an advantage if the enema is easier to squeeze empty," followed by "It would be an advantage if the enema would have a softer point/tip" with a score of 2.2 -this supports the patient suggestions for improvement given above.
Respondents were then asked to select three elements from a list that they felt would improve an enema the most, with the following being the most popular: (1) softness of tip (68%); (2) thickness of applicator -thinner circumference (46%); and (3) curved applicator (angle in the tube) (38%).
Patient beliefs in enema medication
Respondents were also requested to report their views on the medication and enemas they use, and how they feel about drugs and medical intervention in general, using a series of questions scored according to the BMQ on a scale of one to five, where a score of one indicated "always" and a score of five, "never." They were asked firstly: "How do you feel about the drug and the enema you are using?" and then asked to give a rating of one to five to the various responses, where one was "strongly disagree" and five was "strongly agree." Average responses are given in Table 7 more time for their patients, they would prescribe fewer medicines."
Discussion
Major results
This study found that respondents were satisfied overall with their enema use, although the largest proportion of respondents rated themselves as neutral (an average score of 4.3 on a ranking scale of one [very dissatisfied] to seven [very satisfied]), with 12% very dissatisfied and 7% very satisfied. The main reason for dissatisfaction was difficulty/ awkwardness of administration (both men and women), but pain was also given. When asked to rate their perception of enema convenience, however, respondents were less satisfied Notes: One = strongly disagree; two = disagree; three = no clear opinion; four = agree; five = strongly agree. Notes: One = strongly disagree; two = disagree; three = no clear opinion; four = agree; five = strongly agree.
Overall, the responses indicate that respondents are aware of their need to take medication -agreeing with the statements that refer to their health without medicine being worse. The response to fears of dependency on medication are overall more neutral, as is the response to the statement "My medicines disrupt my life" and "I am not sufficiently aware of what my meds do."
Respondents were then asked "How do you feel about drugs in general?" and were asked to give a rating of one to five to the various responses, where one was "strongly disagree" and five was "strongly agree." Average responses are given in Table 8 .
Overall, the patient responses tend to be more neutral, although they are slightly higher in response to the statements "Doctors rely too much on drugs" and "If doctors had and a high level of annoyance/perception of difficulty was seen with enema use.
Self-reported adherence to enema medication was overall good, with an average score of 5.6 on a scale of one to seven (moderate to good compliance), which was also reflected in good scores for adherence on the MARS. Two-thirds of respondents reported never switching enema brand, with respondents with CD switching even less frequently than those with UC. Lack of efficacy was given as the main reason for switching, followed by inconvenience due to pain.
Research comparison
Several recent studies have reviewed self-reported treatment adherence in patients with IBD, using the BMQ-Specific scale, Satisfaction with Information about Medicines Scale, or the Morisky Medication Adherence Scale. [38] [39] [40] Two of these found self-reported adherence by patients with IBD to be overstated, compared with more objective methods, 38, 39 although the third reported that the Morisky Medication Adherence Scale was a successful means of identifying adherence. 39 The current study provides yet another comparison point for physicians, patients, governmental bodies, and pharmaceutical companies to become more "patient intelligent" by using the MARS in patients with IBD, along with the BMQ and an original questionnaire designed by the authors. Patient intelligence can be a valuable source of information, helping health care providers to better understand and apply the patient viewpoint to both treatment and health economic models. 41, 42 A gold standard for assessment of adherence in IBD has not yet been developed, and nonadherence can be difficult to identify. [38] [39] [40] Screening tools such as the Morisky Medication Adherence Scale and MARS may be an effective way of monitoring adherence; a recent study reported overestimation of adherence by physicians in 67% of patients studied. 40, 43 In the current study, respondent answers to the questions on their beliefs in enema medication (the BMQ questions) may indicate a potential discordance in doctorpatient communication. As the therapeutic relationship and patient confidence in treatment is thought to be a factor in adherence, 36, 44 and higher patient-physician discordance on wellbeing has been associated with treatment nonadherence, 44 this is an important consideration. Further, a greater focus on patient reported outcomes is needed. It is important that patients feel involved in the decision-making process for their treatment, as this can promote treatment acceptance, which may also improve adherence. 45 
study limitations and future research needs
Potential study limitations include the relatively small size of the sample, and the limited number of treatments represented in this research group. The only types of medication included were mesalazine (Salofalk, Pentasa, and Asacol) and beclomethasone; as this is not a full representation of the treatment types available by enema, further research could include a greater range.
Another potential limitation is that all respondents signed up for involvement via a patient panel (PIP Health), and have all indicated their willingness to discuss their disease. As patient engagement with treatment may relate to adherence, these patients may be more likely to be adherent to treatment than those in the general population. As the adherence data is self-reported, it may also not be fully representative of actual patient adherence.
Real-life data on the views of patients with IBD towards enema use is limited. This study provides a good foundation into patient viewpoints on their IBD, its management, and in particular the use of enemas. Future research could include the wider patient population with IBD, both in The Netherlands, and in other areas of high IBD incidence.
Research and clinical implications
The therapeutic relationship and patient confidence in their treatment and physician are major factors in patient adherence to medication. 36, 44, 46 Adherence scales may be a valuable tool for assessing patient perception of their disease and treatment adherence, and further testing and validation could be supported by more objective methods, such as urine testing. 39 In this study, the patient responses to the questions on their beliefs in enema medication (the BMQ questions) suggests that both patient education and the doctor-patient relationship could be improved in patients with IBD. More patient intelligence on the views of patients with IBD on enema use could potentially improve disease management and QoL.
Enema design is also very important -both in improving patient QoL and in effective drug administration. 30, 47 Given the views that respondents gave on design, it seems that improvements are called for. Firstly, a softer, more flexible bottle to make handling easier and facilitate emptying; secondly, a softer tip which would be less painful to insert; and thirdly, a curved or angled delivery tube which may improve medication delivery.
Conclusion
Disease site is important when considering therapy for IBD, and topically administered treatment can be very effective. Enema use is therefore an important part of therapy, but can be associated with inconvenience and discomfort, and compliance can be poor. This study has provided novel and important insights into patient perception of their enema use, and into factors which may make enema use more comfortable and acceptable. Further work in this area would be valuable to assess insights into enema use and perceptions on drugs and IBD management in a larger population, as would further use and validation of adherence scales in patients with IBD, and redesign of enemas. • Thinner cannula and something so that when you prepare the enema it is immediately warm • A convenient bottle that is easy to squeeze empty! • Fine, the one in this picture is less fine as no harmonica on it that makes it easier to squeeze • Empty bottle is hard to squeeze nozzle is very hard The journal is characterized by the rapid reporting of reviews, original research, methodologies, analytics, modeling, clinical studies and patient surveys across all disease areas. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors. 
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